Cart
sales@molnova.com
BMS-1001 hydrochloride
CAS No. 2113650-04-5
BMS-1001 hydrochloride( BMS 1001 HCl | BMS1001 HCl )
Catalog No. M13360 CAS No. 2113650-04-5
A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 173 | In Stock |
|
| 5MG | 123 | In Stock |
|
| 10MG | 198 | In Stock |
|
| 25MG | 402 | In Stock |
|
| 50MG | 631 | In Stock |
|
| 100MG | 1004 | In Stock |
|
| 200MG | 1349 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-1001 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
-
DescriptionA potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
-
In Vitro——
-
In Vivo——
-
SynonymsBMS 1001 HCl | BMS1001 HCl
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2113650-04-5
-
Formula Weight667.099
-
Molecular FormulaC35H35ClN2O7HCl
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (19.81 mM)
-
SMILESOC[C@H](C(O)=O)NCC1=CC(C)=C(OCC2=CC=CC(C3=CC=C4OCCOC4=C3)=C2C)C=C1OCC5=CC=CC(C#N)=C5.[H]Cl
-
Chemical Name(2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)-D-serine hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Guzik K, et al. J Med Chem. 2017 Jul 13;60(13):5857-5867.
2. Chupak, L.S., and Zheng, X. Compounds useful as immunomodulators. PCT/US2014/053695, (2015).
molnova catalog
related products
-
Rotundine
Rotundine is extracted from Corydalis yanhusuo W. T. Wang.
-
Nivolumab
Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1PD-1PCD-1) with immune checkpoint inhibitory and antineoplastic activities.
-
BMS-1001
A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
